Table 2.

Degree of improvement in OMDS in patients with HAM/TSP during the double-blind treatment period (full analysis set)

Degree of improvement in OMDSa	Mogamulizumab n = 33	Placebo n = 32	p valueb
1	5 (15.2)	6 (18.8)	0.708
No improvementc	28 (84.8)	26 (81.3)

Data are presented as n (%) of patients

^aLowest degree of improvement among the three time points in Cycle 2–Week 4, 8, and 12 in patients who showed improvement of ≥ 1 grade at all three time points

^bWilcoxon rank sum test using normal approximation

^cPatients with no improvement at any time point in Cycle 2–Week 4, 8, or 12 and patients whose OMDS was missing at any point in Cycle 2–Week 4, 8, or 12

HAM/TSP human T-cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis, OMDS Osame motor disability score